Drug Trial Radar · NCT05082259
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Planned (sponsor's estimate)
Start
Mar 2, 2022
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Institute of Cancer Research, United KingdomAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Astex Pharmaceuticals, Inc.; Merck Sharp & Dohme LLC; Cancer Research UK
- First posted
- Oct 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-centre Phase I dose finding and proof-of-concept study of the combination of ASTX660 together with Pembrolizumab with expansion cohorts testing preliminary efficacy in immune-refractory cancers, triple negative breast cancer (TNBC), cervical cancer, and glioblastoma. In contrast to the existing studies combining first-generation cIAP1/2 selective Smac mimetics with immune check point inhibitors, the ASTEROID Phase I clinical trial will be the first trial utilising triple cIAP1/2 and XIAP blockade by ASTX660 as a strategy to maximise immunogenic cell death and the generation of an efficient adaptive immune response. ASTX660 is not simply being used to repeat the data already being acquired with other first generation Smac mimetics. In contrast, we will investigate more in depth the mechanisms by which ASTX660 elicits its therapeutic effects both on tumour and on the host immune system. This will be critical to determine the best strategy to pursue in future later stage tumour specific trials of IAP antagonists in combination with immunotherapy, and to ensure appropriate molecular stratification biomarkers for the greatest benefit to patients.
Conditions
- Advanced Cancer
- Cervical Cancer
- Triple Negative Breast Cancer
Interventions
ASTX660Drug
ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
PembrolizumabDrug
Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier. Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of MTD and RP2DTime frame: 12 months
- Safety and tolerabilityTime frame: 12 months
- Preliminary anti-tumour activity evaluation (in Part B)Time frame: 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cambridge University Hospitals NHS Trust
Cambridge, United Kingdom
The Royal Marden NHS Foundation Trust - Drug Development Unit
Sutton, United Kingdom
The Royal Marsden NHS Foundation Trust - Breast Unit
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.